# FF Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ff-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.ffpharma.com
- Total disclosed funding: $5.3M
- Latest round: Series A (Jan 21, 2013)
- Investors on record: 3

## About

FF Pharmaceuticals is a Belgium-based company specializing in domain name sales, offering the domain name FfPharma.com at a fixed price with a focus on secure transactions and customer support.Founded in 2012 in Belgium, FF Pharmaceuticals operates in the domain name sales sector, providing clients with a reliable platform for purchasing digital assets. The company secured EUR 4.000 mn in Series A funding in January 2013, led by LRM Limburg Investment Company and co-led by Vesalius Biocapital and PMV-Vinnof. This funding marked a significant step in its operational expansion, enabling the company to enhance its service offerings in the digital marketplace.FF Pharmaceuticals specializes in domain name sales, specifically offering the domain name FfPharma.com for a fixed price of EUR 2,999. The company provides a secure transaction process, free transaction support, and payment options tailored for individual and business clients aiming to enhance their online presence across North America and Europe.FF Pharmaceuticals operates on a direct sales model, generating revenue primarily through the sale of domain names at a set price of EUR 2,999, excluding applicable taxes. The company ensures a secure transaction environment and offers transaction support to enhance customer satisfaction and loyalty.Looking forward, FF Pharmaceuticals aims to leverage the EUR 4.000 mn raised during its latest funding round in January 2013 to broaden its market presence. The company plans to enhance its product offerings and expand into new geographic regions, with a strategic focus on increasing its reach within Europe and North America in the upcoming years.

## Funding rounds

- Series A, Jan 21, 2013, $5.3M — LRM, Vesalius Biocapital, PMV

## Investors

- LRM (https://capitalatlas.ai/funds/lrm) — Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Series A